SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?
Abstract
:1. Introduction
2. Methods
3. Cellular and Humoral Immune Response after COVID-19
3.1. Humoral Response
3.2. Cellular Response
3.2.1. Lymphocytopenia
3.2.2. Virus-Specific T Cell Response
4. Serological Response to Full (Two-Dose) mRNA SARS-CoV-2 Vaccination
5. Antibody Waning after Full Vaccination and the Booster Effect
6. SARS-CoV-2-Specific T Cell Response after Full Vaccination and a Booster
7. Clinical Efficacy and Immune Determination of Breakthrough SARS-CoV-2 Infections
8. Hybrid Immunity (Vaccines and Natural Infections)
9. Adoptive Transfer of Specific T Cells against SARS-CoV-2
10. Future Directions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Cordonnier, C.; Einarsdottir, S.; Cesaro, S.; Di Blasi, R.; Mikulska, M.; Rieger, C.; de Lavallade, H.; Gallo, G.; Lehrnbecher, T.; Engelhard, D.; et al. European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: Guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 2019, 19, e200–e212. [Google Scholar] [CrossRef] [PubMed]
- Styczyński, J.; Tridello, G.; Koster, L.; Iacobelli, S.; van Biezen, A.; van der Werf, S.; Mikulska, M.; Gil, L.; Cordonnier, C.; Ljungman, P.; et al. Infectious Diseases Working Party EBMT. Death after hematopoietic stem cell transplantation: Changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020, 55, 126–136. [Google Scholar] [CrossRef] [PubMed]
- Fontana, L.; Strasfeld, L. Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient. Infect. Dis. Clin. N. Am. 2019, 33, 523–544. [Google Scholar] [CrossRef] [PubMed]
- Pérez, A.; Montoro, J.; Hernani, R.; Lorenzo, I.; Hernández-Boluda, J.C.; Giménez, E.; Gómez, M.D.; Balaguer-Roselló, A.; Gonzalez-Barberá, E.; Guerreiro, M.; et al. Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 2020, 22, e13301. [Google Scholar] [CrossRef]
- Langerbeins, P.; Hallek, M. COVID-19 in patients with hematologic malignancy. Blood 2022, 140, 236–252. [Google Scholar] [CrossRef]
- Ljungman, P.; de la Camara, R.; Mikulska, M.; Tridello, G.; Aguado, B.; Zahrani, M.A.; Apperley, J.; Berceanu, A.; Bofarull, R.M.; Calbacho, M.; et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia 2021, 35, 2885–2894. [Google Scholar] [CrossRef]
- Fujii, T.; Hagihara, M.; Mitamura, K.; Nakashima, S.; Ohara, S.; Uchida, T.; Inoue, M.; Okuda, M.; Yasuhara, A.; Murakami, J.; et al. Anti-SARS-CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. Intern. Med. 2022, 61, 1681–1686. [Google Scholar] [CrossRef]
- Candoni, A.; Pizzano, U.; Fabris, M.; Curcio, F.; Fanin, R. Seroconversion and kinetic of anti SARS-CoV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-CoV-2 infection. Hematol. Oncol. 2021, 39, 428–431. [Google Scholar] [CrossRef]
- El Fakih, R.; Haroon, A.; Alfraih, F.; Al-Khabori, M.K.; Alzahrani, M.; Alhuraiji, A.; Hamadah, A.; AlJohani, N.I.; Alahmari, B.; Essa, M.F.; et al. Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the middle East. Bone Marrow Transplant. 2021, 56, 2144–2151. [Google Scholar] [CrossRef]
- Thakkar, A.; Pradhan, K.; Jindal, S.; Cui, Z.; Rockwell, B.; Shah, A.P.; Hamadah, A.; AlJohani, N.I.; Alahmari, B.; Essa, M.F.; et al. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nat. Cancer 2021, 2, 392–399. [Google Scholar] [CrossRef]
- Passamonti, F.; Romano, A.; Salvini, M.; Merli, F.; Porta, M.G.D.; Bruna, R.; Coviello, E.; Romano, I.; Cairoli, R.; Lemoli, R.; et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br. J. Haematol. 2021, 195, 371–377. [Google Scholar] [CrossRef]
- Lee, J.; Park, S.S.; Kim, T.Y.; Lee, D.G.; Kim, D.W. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A nationwide cohort study. Cancers 2021, 13, 471. [Google Scholar] [CrossRef]
- Sjöwall, J.; Hjorth, M.; Gustafsson, A.; Göransson, R.; Larsson, M.; Waller, H.; Nordgren, J.; Nilsdotter-Augustinsson, Å.; Nyström, S. SARS-CoV-2 Specific Antibody Response and T Cell-Immunity in Immunocompromised Patients up to Six Months Post COVID: A Pilot Study. J. Clin. Med. 2022, 11, 3535. [Google Scholar] [CrossRef]
- Maneikis, K.; Šablauskas, K.; Ringelevičiūtė, U.; Vaitekėnaitė, V.; Čekauskienė, R.; Kryžauskaitė, L.; Naumovas, D.; Banys, V.; Pečeliūnas, V.; Beinortas, T.; et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: A national prospective cohort study. Lancet Haematol. 2021, 8, e583–e592. [Google Scholar] [CrossRef]
- Ehmsen, S.; Asmussen, A.; Jeppesen, S.S.; Nilsson, A.C.; Osterlev, S.; Vestergaard, H.; Justesen, U.S.; Johansen, I.S.; Frederiksen, H.; Ditzel, H.J. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell 2021, 39, 1034–1036. [Google Scholar] [CrossRef]
- Piñana, J.L.; López-Corral, L.; Martino, R.; Montoro, J.; Vazquez, L.; Pérez, A.; Martin-Martin, G.; Facal-Malvar, A.; Ferrer, E.; Pascual, M.J.; et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am. J. Hematol. 2022, 97, 30–42. [Google Scholar] [CrossRef]
- Redjoul, R.; Le Bouter, A.; Beckerich, F.; Fourati, S.; Maury, S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet 2021, 398, 298–299. [Google Scholar] [CrossRef]
- Tamari, R.; Politikos, I.; Knorr, D.A.; Vardhana, S.A.; Young, J.C.; Marcello, L.T.; Doddi, S.; Devlin, S.M.; Ramanathan, L.V.; Pessin, M.S.; et al. Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy. Blood Cancer Discov. 2021, 2, 577–585. [Google Scholar] [CrossRef]
- Kimura, M.; Ferreira, V.H.; Kothari, S.; Pasic, I.; Mattsson, J.I.; Kulasingam, V.; Humar, A.; Mah, A.; Delisle, J.S.; Ierullo, M.; et al. Safety and Immunogenicity after a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. Transplant. Cell Ther. 2022, 28, 706.e1–706.e10. [Google Scholar] [CrossRef]
- Piñana, J.L.; López-Corral, L.; Martino, R.; Vazquez, L.; Pérez, A.; Martin-Martin, G.; Gago, B.; Sanz-Linares, G.; Sanchez-Salinas, A.; Villalon, L.; et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. J. Hematol. Oncol. 2022, 15, 54. [Google Scholar] [CrossRef]
- Piñana, J.L.; Garcia-Sanz, R.; Martino, R.; Garcia-Roa, M.; Martin-Martin, G.A.; Risco-Gálvez, I.; Tormo, M.; Martinez-Barranco, P.; Marcos-Corrales, S.; Calabuig, M.; et al. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Adv. 2022, 6, 848–853. [Google Scholar] [CrossRef] [PubMed]
- Piñana, J.L.; Martino, R.; Vazquez, L.; López-Corral, L.; Pérez, A.; Chorão, P.; Avendaño-Pita, A.; Pascual, M.J.; Sánchez-Salinas, A.; Sanz-Linares, G.; et al. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transplant. 2023, 58, 567–580. [Google Scholar] [CrossRef] [PubMed]
- Leclerc, M.; Redjoul, R.; Le Bouter, A.; Beckerich, F.; Robin, C.; Parinet, V.; Pautas, C.; Menouche, D.; Bouledroua, S.; Roy, L.; et al. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients. J. Hematol. Oncol. 2022, 15, 27. [Google Scholar] [CrossRef] [PubMed]
- Clémenceau, B.; Guillaume, T.; Coste-Burel, M.; Peterlin, P.; Garnier, A.; Le Bourgeois, A.; Jullien, M.; Ollier, J.; Grain, A.; Béné, M.C.; et al. SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine. Vaccines 2022, 10, 448. [Google Scholar] [CrossRef] [PubMed]
- Clémenceau, B.; Le Bourgeois, A.; Guillaume, T.; Coste-Burel, M.; Peterlin, P.; Garnier, A.; Jullien, M.; Ollier, J.; Grain, A.; Béné, M.C.; et al. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients. Cells 2022, 11, 3010. [Google Scholar] [CrossRef] [PubMed]
- Jiménez, M.; Roldán, E.; Fernández-Naval, C.; Villacampa, G.; Martinez-Gallo, M.; Medina-Gil, D.; Peralta-Garzón, S.; Pujadas, G.; Hernández, C.; Pagès, C.; et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022, 6, 774–784. [Google Scholar] [CrossRef]
- Bange, E.M.; Han, N.A.; Wileyto, P.; Kim, J.Y.; Gouma, S.; Robinson, J.; Greenplate, A.R.; Hwee, M.A.; Porterfield, F.; Owoyemi, O.; et al. CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Nat Med. 2021, 27, 1280–1289. [Google Scholar] [CrossRef]
- Ssentongo, P.; Ssentongo, A.E.; Voleti, N.; Groff, D.; Sun, A.; Ba, D.M.; Nunez, J.; Parent, L.J.; Chinchilli, V.M.; Paules, C.I. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: A systematic review and meta-analysis. BMC Infect. Dis. 2022, 22, 439. [Google Scholar] [CrossRef]
- Piñana, J.L.; Vazquez, L.; Calabuig, M.; López-Corral, L.; Martin-Martin, G.; Villalon, L.; Sanz-Linares, G.; Conesa-Garcia, V.; Sanchez-Salinas, A.; Gago, B.; et al. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer J. 2023, 13, 8. [Google Scholar] [CrossRef]
- Piñana, J.L.; Martino, R.; García-García, I.; Parody, R.; Morales, M.D.; Benzo, G.; Gómez-Catalan, I.; Coll, R.; De La Fuente, I.; Luna, A.; et al. Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp. Hematol. Oncol. 2020, 9, 21. [Google Scholar] [CrossRef]
- García-Suárez, J.; de la Cruz, J.; Cedillo, Á.; Llamas, P.; Duarte, R.; Jiménez-Yuste, V.; Hernández-Rivas, J.Á.; Gil-Manso, R.; Kwon, M.; Sánchez-Godoy, P.; et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. J. Hematol. Oncol. 2020, 13, 133. [Google Scholar] [CrossRef]
- Sharma, A.; Bhatt, N.S.; St Martin, A.; Abid, M.B.; Bloomquist, J.; Chemaly, R.F.; Dandoy, C.; Gauthier, J.; Gowda, L.; Perales, M.A.; et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study. Lancet Haematol. 2021, 8, e185–e193. [Google Scholar] [CrossRef]
- Notarbartolo, S.; Ranzani, V.; Bandera, A.; Gruarin, P.; Bevilacqua, V.; Putignano, A.R.; Gobbini, A.; Galeota, E.; Manara, C.; Bombaci, M.; et al. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci. Immunol. 2021, 6, eabg5021. [Google Scholar] [CrossRef]
- Chen, L.; Pang, P.; Qi, H.; Yan, K.; Ren, Y.; Ma, M.; Cao, R.; Li, H.; Hu, C.; Li, Y.; et al. Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19. Front. Immunol. 2022, 13, 770982. [Google Scholar] [CrossRef]
- Kalicińska, E.; Szymczak, D.; Zińczuk, A.; Adamik, B.; Smiechowicz, J.; Skalec, T.; Nowicka-Suszko, D.; Biernat, M.; Bogucka-Fedorczuk, A.; Rybka, J.; et al. Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. Cells 2021, 10, 1293. [Google Scholar] [CrossRef]
- van Heijst, J.W.J.; Ceberio, I.; Lipuma, L.B.; Samilo, D.W.; Wasilewski, G.D.; Gonzales, A.M.; Nieves, J.L.; van den Brink, M.R.; Perales, M.A.; Pamer, E.G. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat. Med. 2013, 19, 372–377. [Google Scholar] [CrossRef]
- Muraro, P.A.; Robins, H.; Malhotra, S.; Howell, M.; Phippard, D.; Desmarais, C.; de Paula Alves Sousa, A.; Griffith, L.M.; Lim, N.; Nash, R.A.; et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J. Clin. Investig. 2014, 124, 1168–1172. [Google Scholar] [CrossRef]
- de Koning, C.; Admiraal, R.; Nierkens, S.; Boelens, J.J. Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2018, 2, 428–432. [Google Scholar] [CrossRef]
- Kanakry, C.G.; Coffey, D.G.; Towlerton, A.M.; Vulic, A.; Storer, B.E.; Chou, J.; Yeung, C.C.; Gocke, C.D.; Robins, H.S.; O’Donnell, P.V.; et al. Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight 2016, 1, e86252. [Google Scholar] [CrossRef]
- Suessmuth, Y.; Mukherjee, R.; Watkins, B.; Koura, D.T.; Finstermeier, K.; Desmarais, C.; Stempora, L.; Horan, J.T.; Langston, A.; Qayed, M.; et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire. Blood 2015, 125, 3835–3850. [Google Scholar] [CrossRef]
- Mazzoni, A.; Mukherjee, R.; Watkins, B.; Koura, D.T.; Finstermeier, K.; Desmarais, C.; Mencarini, J.; Caporale, R.; Peruzzi, B.; Antonelli, A.; et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J. Clin. Investig. 2020, 130, 4694–4703. [Google Scholar] [CrossRef] [PubMed]
- Zheng, M.; Gao, Y.; Wang, G.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol. Immunol. 2020, 17, 533–535. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020, 130, 2620–2629. [Google Scholar] [CrossRef] [PubMed]
- Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, K.; Wang, W.; et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020, 71, 762–768. [Google Scholar] [CrossRef] [PubMed]
- Kamińska, D.; Dęborska-Materkowska, D.; Kościelska-Kasprzak, K.; Mazanowska, O.; Remiorz, A.; Poznański, P.; Durlik, M.; Krajewska, M. Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines 2022, 10, 1068. [Google Scholar] [CrossRef]
- Grifoni, A.; Weiskopf, D.; Ramirez, S.I.; Mateus, J.; Dan, J.M.; Moderbacher, C.R.; Rawlings, S.A.; Sutherland, A.; Premkumar, L.; Jadi, R.S.; et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020, 181, 1489–1501.e15. [Google Scholar] [CrossRef]
- Shah, G.L.; DeWolf, S.; Lee, Y.J.; Tamari, R.; Dahi, P.B.; Lavery, J.A.; Ruiz, J.; Devlin, S.M.; Cho, C.; Peled, J.U.; et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J. Clin. Investig. 2020, 130, 6656–6667. [Google Scholar] [CrossRef]
- Fernandez-Ruiz, M.; Aguado, J.M. Severe acute respiratory syndrome coronavirus 2 infection in the stem cell transplant recipient—Clinical spectrum and outcome. Curr. Opin. Infect. Dis. 2021, 34, 654–662. [Google Scholar] [CrossRef]
- Avanzato, V.A.; Matson, M.J.; Seifert, S.N.; Pryce, R.; Williamson, B.N.; Anzick, S.L.; Barbian, K.; Judson, S.D.; Fischer, E.R.; Martens, C.; et al. Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 2020, 183, 1901–1912.e9. [Google Scholar] [CrossRef]
- Aydillo, T.; Gonzalez-Reiche, A.S.; Aslam, S.; van de Guchte, A.; Khan, Z.; Obla, A.; Dutta, J.; van Bakel, H.; Aberg, J.; García-Sastre, A.; et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N. Engl. J. Med. 2020, 383, 2586–2588. [Google Scholar] [CrossRef]
- Thornton, C.S.; Huntley, K.; Berenger, B.M.; Bristow, M.; Evans, D.H.; Fonseca, K.; Franko, A.; Gillrie, M.R.; Lin, Y.-C.; Povitz, M.; et al. Prolonged SARS-CoV-2 infection following rituximab treatment: Clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob. Resist. Infect. Control 2022, 11, 28. [Google Scholar] [CrossRef]
- Morel, A.; Imbeaud, S.; Scemla, A.; Pere, H.; Fourgeaud, J.; Amrouche, L.; Robillard, N.; Planas, D.; Puech, J.; Simon, S.; et al. Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. Am. J. Transplant. 2022, 22, 2099–2103. [Google Scholar] [CrossRef]
- Coronavirus: Information & Resources. Available online: https://www.nationaljewish.org/patients-visitors/patient-info/important-updates/coronavirus-information-and-resources/covid-19-vaccines/vaccine-articles/side-by-side-comparison-covid-19-vaccine (accessed on 1 January 2023).
- Ram, R.; Hagin, D.; Kikozashvilli, N.; Freund, T.; Amit, O.; Bar-On, Y.; Beyar-Katz, O.; Shefer, G.; Moshiashvili, M.M.; Karni, C.; et al. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. Transplant. Cell Ther. 2021, 27, 788–794. [Google Scholar] [CrossRef]
- Dhakal, B.; Abedin, S.M.; Fenske, T.S.; Chhabra, S.; Ledeboer, N.; Hari, P.; Hamadani, M. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy. Blood 2021, 138, 1278–1281. [Google Scholar] [CrossRef]
- Chevallier, P.; Coste-Burel, M.; Le Bourgeois, A.; Peterlin, P.; Garnier, A.; Béné, M.C.; Imbert, B.M.; Drumel, T.; Le Gouill, S.; Moreau, P.; et al. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients. EJHaem 2021, 2, 520–524. [Google Scholar] [CrossRef]
- Cherif, H.; Hoglund, M.; Pauksens, K. Adjuvanted influenza A (H1N1) 2009 vaccine in patients with hematological diseases: Good safety and immunogenicity even in chemotherapy-treated patients. Eur. J. Haematol. 2013, 90, 413–419. [Google Scholar] [CrossRef]
- Hahn, M.; Schnitzler, P.; Schweiger, B.; Kunz, C.; Ho, A.D.; Goldschmidt, H.; Schmitt, M. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica 2015, 100, e285–e288. [Google Scholar] [CrossRef]
- Leclerc, M.; Fourati, S.; Menouche, D.; Challine, D.; Maury, S. Allogeneic haematopoietic stem cell transplantation from SARS-CoV-2 positive donors. Lancet Haematol. 2021, 8, e167–e169. [Google Scholar] [CrossRef]
- ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients Frequently Asked Questions. Version 5.0. Available online: https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients (accessed on 22 March 2022).
- COVID-19 and BMT—EBMT: COVID-19 Vaccines. Version 7, 3 October 2021. Available online: https://www.ebmt.org/sites/default/files/2021-10/COVID%20vaccines%20version%207.22%20-%202021-10-03.pdf (accessed on 1 January 2023).
- Townsend, J.P.; Hassler, H.B.; Sah, P.; Galvani, A.P.; Dornburg, A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc. Natl. Acad. Sci. USA 2022, 119, e2204336119. [Google Scholar] [CrossRef]
- Widge, A.T.; Rouphael, N.G.; Jackson, L.A.; Anderson, E.J.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Pruijssers, A.J.; et al. mRNA-1273 Study Group. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N. Engl. J. Med. 2021, 384, 80–82. [Google Scholar] [CrossRef]
- Doria-Rose, N.; Suthar, M.S.; Makowski, M.; O’Connell, S.; McDermott, A.B.; Flach, B.; Ledgerwood, J.E.; Mascola, J.R.; Graham, B.S.; Lin, B.C.; et al. mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID-19. N. Engl. J. Med. 2021, 384, 2259–2261. [Google Scholar] [CrossRef] [PubMed]
- Huang, A.; Cicin-Sain, C.; Pasin, C.; Epp, S.; Audigé, A.; Müller, N.J.; Nilsson, J.; Bankova, A.; Wolfensberger, N.; Vilinovszki, O.; et al. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. Transplant. Cell Ther. 2022, 28, 214.e1–214.e11. [Google Scholar] [CrossRef] [PubMed]
- Nemet, I.; Kliker, L.; Lustig, Y.; Zuckerman, N.; Erster, O.; Cohen, C.; Kreiss, Y.; Alroy-Preis, S.; Regev-Yochay, G.; Mendelson, E.; et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N. Engl. J. Med. 2022, 386, 492–494. [Google Scholar] [CrossRef] [PubMed]
- Ahmed-Belkacem, A.; Redjoul, R.; Brillet, R.; Ahnou, N.; Leclerc, M.; López-Molina, D.S.; Soulier, A.; Gourgeon, A.; Rodriguez, C.; Maury, S.; et al. Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. Viruses 2022, 14, 1928. [Google Scholar] [CrossRef] [PubMed]
- Uyemura, B.S.; Abid, M.A.; Suelzer, E.; Abid, M.B. Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients—Targeting the target antigen. Bone Marrow Transplant. 2022, 57, 1727–1731. [Google Scholar] [CrossRef]
- Reimann, P.; Ulmer, H.; Mutschlechner, B.; Benda, M.; Severgnini, L.; Volgger, A.; Lang, T.; Atzl, M.; Huynh, M.; Gasser, K.; et al. Efficacy and Safety of Heterologous Booster Vaccination with Ad26.COV2.S after BNT162b2 MRNA COVID-19 Vaccine in Haemato-Oncological Patients with No Antibody Response. Br. J. Haematol. 2022, 196, 577–584. [Google Scholar] [CrossRef]
- Lindemann, M.; Klisanin, V.; Thümmler, L.; Fisenkci, N.; Tsachakis-Mück, N.; Ditschkowski, M.; Schwarzkopf, S.; Klump, H.; Reinhardt, H.C.; Horn, P.A.; et al. Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients. Vaccines 2021, 9, 1075. [Google Scholar] [CrossRef]
- Harrington, P.; Doores, K.J.; Saha, C.; Saunders, J.; Child, F.; Dillon, R.; Saglam, S.; Raj, K.; McLornan, D.; Avenoso, D.; et al. Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients. Cancer Cell 2021, 39, 1448–1449. [Google Scholar] [CrossRef]
- Zuo, J.; Dowell, A.C.; Pearce, H.; Verma, K.; Long, H.M.; Begum, J.; Aiano, F.; Amin-Chowdhury, Z.; Hoschler, K.; Brooks, T.; et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 2021, 22, 620–626. [Google Scholar] [CrossRef]
- Bilich, T.; Nelde, A.; Heitmann, J.S.; Maringer, Y.; Roerden, M.; Bauer, J.; Rieth, J.; Wacker, M.; Peter, A.; Hörber, S.; et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci. Transl. Med. 2021, 13, eabf7517. [Google Scholar] [CrossRef]
- Wellington, D.; Yin, Z.; Kessler, B.M.; Dong, T. Immunodominance complexity: Lessons yet to be learned from dominant T cell responses to SARS-CoV-2. Curr. Opin. Virol. 2021, 50, 183–191. [Google Scholar] [CrossRef]
- Schwarz, M.; Torre, D.; Lozano-Ojalvo, D.; Tan, A.T.; Tabaglio, T.; Mzoughi, S.; Sanchez-Tarjuelo, R.; Le Bert, N.; Lim, J.M.E.; Hatem, S.; et al. Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nat. Biotechnol. 2022, 40, 1680–1689. [Google Scholar] [CrossRef]
- Dalai, S.C.; Dines, J.N.; Snyder, T.M.; Gittelman, R.M.; Eerkes, T.; Vaney, P.; Howard, S.; Akers, K.; Skewis, L.; Monteforte, A.; et al. Clinical validation of a novel T-cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection. Clin. Infect. Dis. 2022, 75, 2079–2087. [Google Scholar] [CrossRef]
- Pagano, L.; Salmanton-García, J.; Marchesi, F.; López-García, A.; Lamure, S.; Itri, F.; Gomes-Silva, M.; Dragonetti, G.; Falces-Romero, I.; van Doesum, J.; et al. COVID-19 in vaccinated adult patients with hematological malignancies: Preliminary results from EPICOVIDEHA. Blood 2022, 139, 1588–1592. [Google Scholar] [CrossRef]
- Shaw, B.; Shortt, J.; Low, M.; Rogers, B.; Kaplan, Z.; Fedele, P.; Gregory, G.; Vilcassim, S.; Gilbertson, M.; Grigoriadis, G.; et al. Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2. Intern. Med. J. 2022, 52, 2172–2175. [Google Scholar] [CrossRef] [PubMed]
- Walls, A.C.; Sprouse, K.R.; Bowen, J.E.; Joshi, A.; Franko, N.; Navarro, M.J.; Stewart, C.; Cameroni, E.; McCallum, M.; Goecker, E.A.; et al. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 2022, 185, 872–880.e3. [Google Scholar] [CrossRef]
- Altarawneh, H.N.; Chemaitelly, H.; Ayoub, H.H.; Tang, P.; Hasan, M.R.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Coyle, P.; Al-Kanaani, Z.; et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022, 387, 21–34. [Google Scholar] [CrossRef]
- Goldberg, Y.; Mandel, M.; Bar-On, Y.M.; Bodenheimer, O.; Freedman, L.S.; Ash, N.; Alroy-Preis, S.; Huppert, A.; Milo, R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 2022, 386, 2201–2212. [Google Scholar] [CrossRef]
- Arcani, R.; Colle, J.; Cauchois, R.; Koubi, M.; Jarrot, P.A.; Jean, R.; Boyer, A.; Lachamp, J.; Tichadou, A.; Couderc, A.L.; et al. Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that pro-longed SARS-CoV-2 carriage is an important issue. Ann. Hematol. 2021, 100, 2799–2803. [Google Scholar] [CrossRef]
- Jiang, M.; Guo, Y.; Luo, Q.; Huang, Z.; Zhao, R.; Liu, S.; Li, J.; Wan, L. T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J. Infect. Dis. 2020, 222, 198–202. [Google Scholar] [CrossRef]
- Huang, W.; Berube, J.; McNamara, M.; Saksena, S.; Hartman, M.; Arshad, T.; Bornheimer, S.J.; O’Gorman, M. Lymphocyte subset counts in COVID-19 patients: A meta-analysis. Cytom. A 2020, 97, 772–776. [Google Scholar] [CrossRef] [PubMed]
- García-García, I.; Guerra-García, P.; Ferreras, C.; Borobia, A.M.; Carcas, A.J.; Queiruga-Parada, J.; Vicario, J.L.; Mirones, I.; Solano, C.; Eguizabal, C.; et al. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. Trials 2021, 22, 674. [Google Scholar] [CrossRef] [PubMed]
- Pérez-Martínez, A.; Mora-Rillo, M.; Ferreras, C.; Guerra-García, P.; Pascual-Miguel, B.; Mestre-Durán, C.; Borobia, A.M.; Carcas, A.J.; Queiruga-Parada, J.; García, I.; et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). EClinicalMedicine 2021, 39, 101086. [Google Scholar] [CrossRef] [PubMed]
- Leung, W.; Soh, T.G.; Linn, Y.C.; Low, J.G.; Loh, J.; Chan, M.; Chng, W.J.; Koh, L.P.; Poon, M.L.; Ng, K.P.; et al. Rapid production of clinical-grade SARS-CoV-2 specific T cells. Adv. Cell Gene Ther. 2020, 3, e101. [Google Scholar] [CrossRef] [PubMed]
- Bonifacius, A.; Tischer-Zimmermann, S.; Santamorena, M.M.; Mausberg, P.; Schenk, J.; Koch, S.; Barnstorf-Brandes, J.; Gödecke, N.; Martens, J.; Goudeva, L.; et al. Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy. Front. Bioeng. Biotechnol. 2022, 10, 867042. [Google Scholar] [CrossRef]
- Guerreiro, M.; Aguilar-Gallardo, C.; Montoro, J.; Francés-Gómez, C.; Latorre, V.; Luna, I.; Planelles, D.; Carrasco, M.P.; Gómez, M.D.; González-Barberá, E.M.; et al. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients? Transpl. Infect. Dis. 2021, 23, e13602. [Google Scholar] [CrossRef]
- Basar, R.; Uprety, N.; Ensley, E.; Daher, M.; Klein, K.; Martinez, F.; Aung, F.; Shanley, M.; Hu, B.; Gokdemir, E.; et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep. 2021, 36, 109432. [Google Scholar] [CrossRef]
- Peter, L.; Wendering, D.J.; Schlickeiser, S.; Hoffmann, H.; Noster, R.; Wagner, D.L.; Zarrinrad, G.; Münch, S.; Picht, S.; Schulenberg, S.; et al. Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Mol. Ther. Methods Clin. Dev. 2022, 25, 52–73. [Google Scholar] [CrossRef]
- Ferreras, C.; Pascual-Miguel, B.; Mestre-Durán, C.; Navarro-Zapata, A.; Clares-Villa, L.; Martín-Cortázar, C.; De Paz, R.; Marcos, A.; Vicario, J.L.; Balas, A.; et al. SARS-CoV-2-Specific Memory T Lymphocytes from COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy. Front. Cell Dev. Biol. 2021, 9, 620730. [Google Scholar] [CrossRef]
Clinical Context | Low Antibody Production | Antibody Decline | Lower Celullar Immunity | Lower Severity | Breakthrough Infection |
---|---|---|---|---|---|
Natural Infection |
|
|
|
| |
Full mRNA Vaccination |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Piñana, J.L.; Guerreiro, M.; Solano, C. SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined? Hemato 2023, 4, 170-183. https://doi.org/10.3390/hemato4020014
Piñana JL, Guerreiro M, Solano C. SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined? Hemato. 2023; 4(2):170-183. https://doi.org/10.3390/hemato4020014
Chicago/Turabian StylePiñana, José Luis, Manuel Guerreiro, and Carlos Solano. 2023. "SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?" Hemato 4, no. 2: 170-183. https://doi.org/10.3390/hemato4020014